
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around $23.61 on Sept. 25.
This is welcome news to long-term holders who have endured a significant dip in the stock since its vaccine-fueled surge in 2021. PFE stock trades at an attractive multiple of around 9x forward earnings and is a steady dividend payer with a dividend yielding 6.4%.